Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression

Curr Oncol Rep. 2009 Jan;11(1):1-2. doi: 10.1007/s11912-009-0001-y.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic / methods
  • Clinical Trials as Topic / standards*
  • Disease Progression
  • Disease-Free Survival
  • Humans
  • Medical Oncology / methods
  • Neoplasms / drug therapy*
  • Neoplasms / pathology*
  • Prospective Studies
  • Research Design*
  • Taxoids / pharmacology
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Taxoids